A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
(HERKULES-2 Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing two new drugs, ERAS-007 and ERAS-601, in combination with other treatments for advanced lung cancer patients with specific genetic mutations. The goal is to see if these new drugs can enhance the effectiveness of existing treatments by targeting specific pathways in the cancer cells.
Will I have to stop taking my current medications?
The trial requires that you do not take any other systemic anticancer therapy for NSCLC while participating. If you are currently on such treatments, you would need to stop them before joining the trial.
What data supports the effectiveness of the treatment ERAS-007, ERAS-601?
Research Team
Joyce Antal
Principal Investigator
Senior Director, Clinical Development
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
ERAS-007 or ERAS-601 is administered in combination with other therapies in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent
Dose Expansion
ERAS-007 or ERAS-601 is administered at the recommended dose in combination with other therapies to evaluate safety and antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ERAS-007
- ERAS-601
Find a Clinic Near You
Who Is Running the Clinical Trial?
Erasca, Inc.
Lead Sponsor